🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

❓Wondering whats new in stage IV #cancer? Incidence of mets in #breastcancer or #prostatecancer? Role of 🧬genomics, ☢️PET, #radonc or lifestyle mods? 🇺🇸🇨🇭🇨🇦🇧🇪🇮🇹🇫🇷🇦🇺 Eric Lehrer, MD and Nicholas Zaorsky, MD MS lead an international cast to address these questions shorturl.at/gWNlQ

1/ The Dutch ESLUNG study is potentially the largest prospective registry (n=2,183) evaluating outcomes for stage I NSCLC treated with minimally invasive surgery or SABR. Their non-randomized data, when propensity-matched, show similar findings to those previously reported by the

Controversy remains the major issue for combining radiotherapy with immunotherapy. Please see our recent publication in Lancet Oncology led by working group sponsored by NCI. My personalized Share Link: authors.elsevier.com/c/1kiL65EIIgPe…

Celebrating our first new-generation resident as she completes her specialization in Radiation Oncology! Proud of all our young residents—our legacy, our future! #pink #radonc UniversitàVanvitelli youngAIRO

Hot of the press IJROBP - The Red Journal: Role of SABR in oligometastatic head and neck cancer: a GORTEC randomized trial Full text here: doi.org/10.1016/j.ijro…

🫁 Selective SBRT can help patients with metastatic EGFR+ NSCLC get more MILEAGE out of every one of these drugs. Ask your radiation oncologist to learn more. Jill Feldman GO2 for Lung Cancer LUNGevity Foundation LungCancerAmerica ACS National Lung Cancer Roundtable

Review: Antonin Levy, Christophe Massard, Stefan Michiels, and Eric Deutsch highlight the latest developments and future directions for early-phase clinical trials that combine precision drug–radiotherapy strategies #radiotherapy thelancet.com/journals/lanon…

Through an exhaustive search, we found that <2% of NCI funding supported radiation oncology research despite the fact that over 50% of cancer patients receive radiation during their lifetime.

HYPO-RT-PC 10-year results! UHF RT (42.7 Gy/7 fx) shows non-inferior failure-free survival vs CRT (78 Gy/39 fx): - 72% vs 65% 10Y Long-term tox: - No significant differences in grade ≥2 GU/GI events UHF-RT as a safe, effective, and efficient standard for localized PCa .

📢10 years outcomes from the HYPO-RT-PC trial confirmed the non-inferiority of ultrahypof. Schedule in terms of failure free survival, with no difference in terms of late GU or GI tox.#ESTRO25 ,ESTRO

Proud of co-chairing with ESMO - Eur. Oncology President Elect G Curigliano MD PhD the ESMO-ESTRO joint session on combinatory strategies between #Radiotherapy and new system therapies Transformative innovation through partnership💪🏼💪🏼 #ESTRO25 OncoAlert #radonc #medonc ESTRO #OncoAlert

Completely agree with Dr. Nina Niu Sanford ! An excellent presentation on radiation omission trials. It's time to shift how both professionals and patients perceive radiation therapy. #ESTRO25

Amazing Pierluigi Bonomo at the meet the expert session on head and neck guidelines in delineation #ESTRO25 ROs essential in the preoperative decision making process #radonc #OncoAlert OncoAlert

Regional nodes: what are the optimal approaches in 2025? Exciting educational session led by science masters #ESMOBreast25 ESMO - Eur. Oncology OncoAlert #OncoAlert #radonc #BreastCancer

Is stereotactic #radiosurgery the standard of care for #breastcancer patients with multiple brain met? Honoured to contribute with Nancy Lin in this Controversy Session chaired by Philip Poortmans Strong emphasis on patient-centred perspectives #ESMOBreast25 ESMO - Eur. Oncology OncoAlert

Lo Scudetto torna a Casa…𝑨𝑮𝟒𝑰𝑵! Il Napoli è Campione d’Italia! 💙 #AG4IN #ProudToBeNapoli

🧵1/ Big news in unresectable stage III NSCLC. The InTRist study is the first randomized trial comparing NAC vs. neoadjuvant chemoimmunotherapy (NAC-ICI) prior to definitive chemoradiotherapy (CRT). Early results are promising. Let’s dig in. 🔍 #LungCancer #RadOnc #ASCO25

EBRT is conspicuously absent, while TACE, with ~50% local failure rates, continues to be elevated despite having some of the worst LF rates of any so-called “local control” modality across oncology. We can do better. #HCC BCLC best for prognostication, not treatment algorithms.

Proud to contribute to this important study on TNT for rectal cancer led by Francesco Sclafani 👇 pubmed.ncbi.nlm.nih.gov/40638097/

Phase III Study of Mediastinal Lymph Node Dissection for Ground Glass Opacity–Dominant Lung Adenocarcinoma. Read the full article. brnw.ch/21wUqiZ